Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ATF4 | P18848 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20061878 | 0.84 | LMNA (0.44) | SIGMAR1MEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL13681670 | 0.84 | NPSR1 (0.52) | MEN1KMT2ANPSR1ATF4 | |
| SCHEMBL22332304 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KMT2ANPSR1MAPT | |
| SCHEMBL22332323 | 0.82 | ATF4 (0.43) | EPHX1EPHX2MEN1ALDH1A1KMT2A | |
| SCHEMBL19764241 | 0.82 | EPHX1 (0.58) | EPHX1EPHX2MEN1ALDH1A1KMT2A | |
| SCHEMBL20061877 | 0.82 | KDM4E (0.45) | EPHX1EPHX2MEN1ALDH1A1KMT2A | |
| SCHEMBL20071680 | 0.81 | EPHX1 (0.57) | EPHX1EPHX2SIGMAR1MEN1ALDH1A1 | |
| SCHEMBL22332321 | 0.81 | NPSR1 (0.41) | EPHX2MEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL12101985 | 0.80 | NPSR1 (0.58) | EPHX1MEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL12708609 | 0.79 | NPSR1 (0.66) | EPHX1MEN1ALDH1A1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | TPSD1, TPSAB1, TMSB4X | EPHX1 4135/4885EPHX2 4331/4885SIGMAR1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.